MX2019002108A - Terapia de combinacion con inhibidores de glutaminasa. - Google Patents

Terapia de combinacion con inhibidores de glutaminasa.

Info

Publication number
MX2019002108A
MX2019002108A MX2019002108A MX2019002108A MX2019002108A MX 2019002108 A MX2019002108 A MX 2019002108A MX 2019002108 A MX2019002108 A MX 2019002108A MX 2019002108 A MX2019002108 A MX 2019002108A MX 2019002108 A MX2019002108 A MX 2019002108A
Authority
MX
Mexico
Prior art keywords
combination therapy
glutaminase inhibitors
methods
treating cancer
myeloproliferative
Prior art date
Application number
MX2019002108A
Other languages
English (en)
Inventor
Parlati Francesco
Orford Keith
H Whiting Sam
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MX2019002108A publication Critical patent/MX2019002108A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a métodos para tratar cáncer o enfermedades mieloproliferativas con una combinación de un inhibidor de glutaminasa y un agente anticáncer seleccionado de cabozantinib, crizotinib, y axitinib. La invención además se refiere a métodos para tratar cáncer o enfermedades mieloproliferativas que son resistentes a uno o más agentes anticáncer.
MX2019002108A 2016-08-25 2017-08-25 Terapia de combinacion con inhibidores de glutaminasa. MX2019002108A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379604P 2016-08-25 2016-08-25
PCT/US2017/048581 WO2018039544A1 (en) 2016-08-25 2017-08-25 Combination therapy with glutaminase inhibitors

Publications (1)

Publication Number Publication Date
MX2019002108A true MX2019002108A (es) 2019-07-08

Family

ID=61240223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002108A MX2019002108A (es) 2016-08-25 2017-08-25 Terapia de combinacion con inhibidores de glutaminasa.

Country Status (12)

Country Link
US (2) US10278968B2 (es)
EP (1) EP3503886A4 (es)
JP (1) JP2019526560A (es)
KR (1) KR20190040302A (es)
CN (1) CN110139649A (es)
AU (1) AU2017315446A1 (es)
BR (1) BR112019003533A2 (es)
CA (1) CA3034890A1 (es)
EA (1) EA201990567A1 (es)
MX (1) MX2019002108A (es)
SG (1) SG11201901389XA (es)
WO (1) WO2018039544A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211610T1 (hr) 2012-11-16 2022-02-04 Calithera Biosciences, Inc. Inhibitori heterocikličke glutaminaze
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
MX2017012824A (es) 2015-04-06 2018-05-15 Calithera Biosciences Inc Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
AU2016335991A1 (en) 2015-10-05 2018-05-10 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
EP3503886A4 (en) 2016-08-25 2020-07-22 Calithera Biosciences, Inc. POLYTHERAPY INCLUDING GLUTAMINASE INHIBITORS
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US11590122B2 (en) 2021-02-19 2023-02-28 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
KR20230001587A (ko) * 2021-06-28 2023-01-05 연세대학교 산학협력단 암의 예방 또는 치료용 약학 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
AU2005245785B2 (en) 2004-04-15 2011-04-07 Banyan Biomarkers Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
WO2009104696A1 (ja) 2008-02-19 2009-08-27 株式会社アーネストメディスン 身体機能の回復に有用な経口又は経腸組成物
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
JP2013543009A (ja) 2010-11-18 2013-11-28 デューテリア ファーマシューティカルズ， インコーポレイテッド ３−ジュウテロ−ポマリドマイド
CN103030597B (zh) 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
JP6031527B2 (ja) * 2011-11-21 2016-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼのヘテロ環式阻害剤
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
CA2884103A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
HRP20211610T1 (hr) * 2012-11-16 2022-02-04 Calithera Biosciences, Inc. Inhibitori heterocikličke glutaminaze
BR112015011756A2 (pt) 2012-11-21 2017-07-11 Agios Pharmaceuticals Inc inibidores da glutamase e métodos de uso
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
JP6285950B2 (ja) 2012-12-03 2018-02-28 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼの複素環式阻害剤を用いるがんの処置
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
EP3154590B1 (en) * 2014-06-13 2021-04-14 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
SG11201708034SA (en) 2015-03-30 2017-10-30 Calithera Biosciences Inc Methods of administering glutaminase inhibitors
MX2017012824A (es) 2015-04-06 2018-05-15 Calithera Biosciences Inc Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
EP3503886A4 (en) 2016-08-25 2020-07-22 Calithera Biosciences, Inc. POLYTHERAPY INCLUDING GLUTAMINASE INHIBITORS
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2018039442A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase

Also Published As

Publication number Publication date
US20180055843A1 (en) 2018-03-01
EA201990567A1 (ru) 2019-08-30
CN110139649A (zh) 2019-08-16
KR20190040302A (ko) 2019-04-17
AU2017315446A1 (en) 2019-03-07
SG11201901389XA (en) 2019-03-28
US10278968B2 (en) 2019-05-07
EP3503886A1 (en) 2019-07-03
EP3503886A4 (en) 2020-07-22
WO2018039544A1 (en) 2018-03-01
BR112019003533A2 (pt) 2019-05-21
CA3034890A1 (en) 2018-03-01
US20190275038A1 (en) 2019-09-12
JP2019526560A (ja) 2019-09-19

Similar Documents

Publication Publication Date Title
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2022008868A (es) Tratamiento del cancer con tg02.
MD20170073A2 (ro) Terapii combinate pentru tratarea cancerelor
PH12017502103A1 (en) Methods and kits for treating depression
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX2017010002A (es) Terapias de combinacion.
MX2017009246A (es) Farmaco de combinacion.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.